Penumbra (PEN) is back in focus after new clinical data from its STORM-PE and STRIKE-PE studies linked real-world wearable activity to recovery outcomes in pulmonary embolism patients treated with its CAVT technology.
Recent clinical headlines have landed against a relatively quiet tape for Penumbra, with the share price easing 1.8% over the past month and 0.6% over the past week, even as the year-to-date share price return is positive and the 1-year total shareholder return of 22.2% points to momentum that has been building over a longer horizon.
Spot similar PE treatment and medtech momentum by scanning the hand-picked 34 healthcare AI stocks , which tie real-world patient outcomes to data driven devices.
Penumbra now trades about 14% below the average analyst target after a modest pullback, even as its 1-year return tops 22%. Is that discount a patient opportunity, or is it simply a reflection of justified caution on execution and valuation?
Most Popular Narrative: 13% Undervalued
Penumbra's most followed valuation storyline pegs fair value at $361.83 using a 7.52% discount rate, compared with the last close at $316.35. This frames today's pullback as a gap between clinical traction, earnings power, and what the current share price reflects.
The embolization franchise, led by Ruby XL and Swift coils with strong middle meningeal artery embolization uptake and backed by a dedicated embolization sales team of more than 50 people, is emerging as a second pillar alongside thrombectomy. It can increasingly contribute to revenue diversification and operating margin leverage.
See why 5 investors see Penumbra as 13% undervalued .
Result: Fair Value of $361.83 (UNDERVALUED)
Still, the Penumbra story can wobble if Boston Scientific integration drags on margins or if another earnings miss like Q1 2026 resets investor expectations.
Find out about the key risks to this Penumbra narrative .
Another View On Penumbra's Valuation
That 13% "undervalued" fair value story appears very different when you look at Penumbra through its P/E. The shares trade on 77.6x earnings, compared with 24.5x for the US Medical Equipment industry, 22.4x for peers, and a fair ratio of 28.3x that the market could move toward over time.
Such a wide gap signals valuation risk, because even solid execution could still coincide with a lower multiple. The key question is whether you think Penumbra's growth and margins are strong enough to justify that premium, or whether mean reversion in the P/E is the more important factor to watch.
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
Feeling torn between the enthusiasm in Penumbra's story and the valuation questions raised here? Act while the data is fresh in your mind and pressure test the upside case by reviewing the 2 key rewards .
Looking For More Ideas Beyond Penumbra?
Do not stop your research with Penumbra when a wider universe of opportunities is only a few clicks away and could sharpen every decision you make.
-
Target dependable income streams by scanning a curated pool of higher yielding payers through the 8 dividend fortresses .
-
Hunt for quality at a discount by reviewing the hand picked 29 high quality undervalued stocks that combine strong fundamentals with prices that lag underlying strength.
-
Protect your downside by focusing on companies with sturdier finances through the focused list of solid balance sheet and fundamentals (25 results) .
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include PEN .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
